July 2016 Newsletter
Comments Welcomed for the Revisions to the Molecular Testing Guideline
The College of American Pathologists (CAP), International Association for the Study of Lung Cancer (IASLC), and Association for Molecular Pathology (AMP) invite you to comment on the draft recommendations for revising the Molecular Testing Guideline for lung cancer patients for Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitors.
Public feedback is seen as instrumental to this process, helping to identify gaps in proposed guidance and ensuring that the guideline produces proper testing and treatment. The CAP/IASLC/AMP Lung Biomarkers Update Expert Panel was convened in 2015 to perform a systematic literature review and develop the practice guideline recommendations.
Download a full copy of the review recommendations, and share your comments with the Expert Panel in charge of the guideline revisions before the August 2 deadline. The panel looks forward to reviewing your comments and thanks you for your input.
Read the Second Issue of IASLC Lung Cancer News
In case you missed the announcement in our last newsletter, the second issue of IASLC Lung Cancer News is now available online. This issue features:
To read the publication online simply follow this link, or download a PDF of the publication. IASLC invites readers to submit article ideas, in addition to new content for future “Names and News” columns, to firstname.lastname@example.org. All submissions are subject to review and approval by the magazine’s editor, and selection for publication is not guaranteed.
Regional Organizing Committee Application (ROC) for WCLC 2019 (Europe)
Applications are now being accepted for parties interested in forming a Regional Organizing Committee (ROC) for IASLC's 20th World Conference on Lung Cancer (WCLC), which will take place in Barcelona, Spain in November 2019. The ROC will be composed of 15-20 IASLC members, and will provide regional leadership to help develop the WCLC's scientific program, social events, and overall logistical plan.
Other responsibilities of the ROC include planning onsite workshops, arranging travel grants and awards, and assisting with press releases and marketing efforts. For a full description of the ROC's role and a link to the application, please visit our website or download the application.
Get Ready for World Lung Cancer Day
Mark your calendars and get ready for 2016's World Lung Cancer Day, taking place on August 1, 2016. World Lung Cancer Day is designed to celebrate, commemorate, and support the lives affected by lung cancer.
We encourage our members to help get the word out regarding the facts of lung cancer. IASLC has compiled fact sheets to assist with this effort, which are available in English, Chinese, Japanese, Korean, Spanish, and Portuguese.
There is also an active event page for World Lung Cancer Day on Facebook that provides a forum for those affected by lung cancer. Facebook users are able to share their stories and connect with others on this page. We strongly encourage our members to join this event and continue to raise awareness and inspire engagement in the global fight against lung cancer.
Academic, Career, and Funding Opportunities
As a service to our members, we post opportunities related to lung cancer and other thoracic malignancies on our website.
This now includes academic career opportunities. Click here to review post-doctoral and other career opportunities submitted to IASLC. If you have an academic career opportunity, please email it to email@example.com.
We also post opportunities when we receive information from grantors. We currently have three funding opportunities:
These opportunities are available to applicants from all countries. Click here to learn more.
Social Media Corner: Connecting the Community
By Tom John, Austin Health and Olivia Newton John Cancer Research Institute, Melbourne, Australia
Social media platforms such as Twitter have completely changed the way medical professionals interact with peers, colleagues, and the general public.
Growing your Twitter network can broaden and enrich the overall experience. However, you cannot edit tweets once they have been sent. Your views are also accessible to everyone, which could include your patients or research grant competitors.
However, the risks do not overshadow the rewards. At ASCO this year, the number of Twitter users doubled from their previous meeting, with many following the events and activities virtually over Twitter. Twitter is an excellent resource to connect and share perspectives on papers, data, and studies. It also provides access to a wealth of new information shared by others.
July 2016: The IASLC and the Journal of Thoracic Oncology (JTO) are pleased to present the Editor's Choice each month to highlight certain articles of interest. The selected article will be made available to the public for a limited time upon printing. The articles below from the July issue of the JTO are free for three months. Please share with your colleagues around the globe!
Alex A. Adjei, MD, PhD
There is significant interest in the development and natural history of subsolid nodules (SSNs). Kakinuma and colleagues attempt to address this issue in this first featured article and Dr. Samjot Dhillon provides a thoughtful, accompanying editorial.
Aggarwal and colleagues have performed a comprehensive analysis of the investments in lung cancer research made by a number of countries over the ten-year period from 2003-2014. This research forms the basis of the second featured article.
Phase II Trial of Stereotactic Body Radiotherapy for Stage I NSCLC: Survival, Local Control, and Lung Function at 36 Months
Stereotactic body radiotherapy (SBRT) is being more frequently utilized in patients with inoperable non-small cell lung cancer (NSCLC). A pilot phase II study authored by Navarro-Martin and colleagues evaluates the long term outcome of SBRT on respiratory function as well as survival. While small, this study provides the basis for performing larger and more definitive studies in the future.
Lung cancer is universally accepted as a disease of the elderly, and yet there are young patients who also develop this disease. Very little is known about the outcome of these young patients. Arnold and colleagues utilized the U.S. National Cancer Data Base to evaluate the outcome of 5,657 young (defined as ages 20 – 46) patients with non-small cell lung cancer.
The following article was selected from the JTO by the IASLC Communications Committee to be promoted to the media and the public with press releases that were released at the time of online publication (Published Ahead of Print).
To read more IASLC Press Releases, please visit IASLC Research Articles. These press releases are also announced via social media, so please follow IASLC on Twitter, LinkedIn, and Facebook to stay up to date on the latest scientific topics.
Adjuvant Chemotherapy Improves Overall Survival in Patients With Stage IB Non-Small Cell Lung Cancer
The use of adjuvant chemotherapy in early-stage non-small cell lung cancer (NSCLC) patients improves overall survival (OS) and 5-year OS in patients with tumor sizes ranging from 3.1 – 7 cm.
Young Tae Kim, MD. PhD.
Update from Korean Regent, Young Tae Kim:
The Korean Association For Lung Cancer (KALC) 2016 Spring Conference was held at Haeundae Grand Hotel, on June 24 in Busan, Korea. More than 400 participants from various specialties, including thoracic surgeons, medical oncologists, radiation oncologists, pulmonologists, radiologists, pathologists and nurses, attended and discussed the latest developments in lung cancer treatment.
Distinguished speakers presented on and discussed the 8th Edition of the TNM Staging Classification for lung cancer and 2016 WHO Classification. In the interactive discussion session, a case of recurrent non-small cell lung cancer (NSCLC) and a case of GGN lesion were debated in depth, providing a unique opportunity for participants to share experiences.
Promotional IASLC membership materials were on display at registration, and registrants received copies of IASLC Multidisciplinary Approach to Thoracic Oncology textbook, provided by the IASLC home office.
South Korean IASLC membership stands at 130, an increase of 10 percent from the previous year. There is also a special discount for KALC members to join IASLC. This joint membership recognizes the collaborative relationship and shared mission of the two organizations. It provides two discounted membership rates for KALC members to choose between: A one-year (USD $125) or three-year (USD $475) IASLC membership. Learn more: https://www.iaslc.org/kaslc-special-offer. If you have any questions, please contact firstname.lastname@example.org or KALC@lungca.or.kr.
There are two ways you can access the JTO:
1. Login via the IASLC Membership Portal with your username and password. Once signed in, select “JTO Member Access” from the left hand menu and click “Journal of Thoracic Oncology.” Here you will have access to the JTO articles free for members.
2. To get selected features on the Elsevier website like Publish-Ahead-of-Print (PAP) alerts, individual search history, or saved articles, you can also set up a custom account on the new www.jto.org site. If you have not already done so, click here to set up an account and continue to follow the steps below:
a. Click Create Account, then complete the "Register a New Account" form and click "Register."
b. On the "Claim Online Access" page, select “I receive my subscription through a society membership”
*Please note that you will need to enter your IASLC member ID number on the first visit in order to claim your subscriber access. You will then enter a new password which will suffice for future visits to the JTO website.
Should you have any questions regarding your access to the online JTO, please contact our Membership team at: email@example.com.
Free Membership for Patients/Survivors
IASLC has launched a free membership for patients and survivors of any thoracic malignancy. All patients/survivors with a diagnosis of lung cancer, mesothelioma, or other thoracic cancers qualify for the free membership. Patients and survivors can renew this non-voting membership annually. Except for voting, the patient/survivor membership includes all Allied Health Professional member benefits, and includes online access to the JTO, member meeting discounts, eligibility to apply for travel awards, and eligibility to serve on Committees.
IASLC Continues Series of Patient Advocate Meetings:
A former professional football player, Chris Draft is the founder, president and CEO of the Chris Draft Family Foundation (CDFF). Chris became intimately involved with lung cancer following the passing of his wife Keasha, who died from the disease in 2012. He now uses his connections to the NFL to raise awareness for the disease. During the meeting, Chris gave a presentation to the IASLC staff on the importance of making lung cancer relatable, highlighting encouraging developments the field, and advancing a culture of hope. These sentiments were echoed by Kathy Weber and Lisa Moran, who shared stories of their own journeys with lung cancer and their reasons to be hopeful for the future.
All in all, it was an illuminating and productive meeting that emphasized how changing the narrative of lung cancer is necessary to increase public awareness, engagement, and to push for new research and funding.
IASLC WCLC 2016 Patient Advocacy Awards Announced – Open for Submission
Become a Member
Join the only international association solely dedicated to lung cancer research and treatment.
WCLC Virtual Library
September 23 - 26 2018Toronto, Canada
November 8 - 10 2018Guangzhou, China
February 20 - 23 2019Santa Monica, California